Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single arm, multicentric, open label, efficacy and safety study of Docetaxel Lipid Suspension for Injection of Intas Pharmaceuticals Limited, India in patients with Metastatic Castration Resistant prostate cancer

Next Previous
Trial Profile

A single arm, multicentric, open label, efficacy and safety study of Docetaxel Lipid Suspension for Injection of Intas Pharmaceuticals Limited, India in patients with Metastatic Castration Resistant prostate cancer

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Intas Pharmaceuticals

    • Most Recent Events

    • 25 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top